Add a GLP-1 Receptor Agonist to Metformin
Given the rash from empagliflozin (Jardiance), you should add a GLP-1 receptor agonist such as semaglutide, dulaglutide, or tirzepatide to the existing metformin regimen. 1
Rationale for GLP-1 Agonist Selection
The American College of Physicians 2024 guideline strongly recommends adding either an SGLT-2 inhibitor or a GLP-1 agonist to metformin when glycemic control is inadequate (A1c 8.3% qualifies), with GLP-1 agonists specifically reducing all-cause mortality, major adverse cardiovascular events (MACE), and stroke. 1
Since the patient developed a hypersensitivity reaction (rash) to empagliflozin—a documented adverse effect that requires immediate discontinuation per FDA labeling—the SGLT-2 inhibitor class should be avoided, making a GLP-1 agonist the next logical choice. 2
GLP-1 agonists are particularly appropriate when weight loss is a treatment goal, and they do not cause hypoglycemia when combined with metformin alone. 1
Expected Glycemic Benefit
In patients with baseline A1c >9%, GLP-1 receptor agonists reduce A1c by approximately 2.5–3.1%, which would bring this patient's A1c from 8.3% to a target range of 6–7%. 3
Head-to-head trials comparing GLP-1 agonists with basal insulin in patients with A1c ≥9% showed equal or superior A1c reduction with GLP-1 therapy (3.1% reduction with liraglutide vs. insulin glargine in patients with baseline A1c 10.6%), but with the added benefit of weight loss rather than weight gain. 3
Practical Implementation
Start with a once-weekly GLP-1 agonist (semaglutide 0.25 mg weekly, dulaglutide 0.75 mg weekly, or tirzepatide 2.5 mg weekly) to maximize adherence, then titrate upward every 4 weeks based on tolerability and glycemic response. 1
Continue metformin 2000 mg daily unless gastrointestinal side effects emerge; if they do, switch to extended-release formulation or take with meals to reduce symptoms by approximately 50%. 4
Counsel the patient on common GLP-1 side effects (nausea, vomiting, diarrhea) that typically diminish after 4–8 weeks, and advise slow dose escalation to minimize these effects. 1
Why Not Other Options
DPP-4 inhibitors (sitagliptin, linagliptin) are explicitly not recommended by the American College of Physicians because they do not reduce morbidity or all-cause mortality compared to placebo. 1
Sulfonylureas and basal insulin are inferior to both SGLT-2 inhibitors and GLP-1 agonists for reducing mortality and cardiovascular events, and they carry significant hypoglycemia risk. 1
Although triple therapy (metformin + DPP-4 inhibitor + SGLT-2 inhibitor) has been studied in drug-naïve patients with very high A1c (>11%), the evidence for benefits beyond initial dual therapy is lacking, and the patient's rash precludes SGLT-2 inhibitor use. 1, 5
Monitoring and Follow-Up
Reassess A1c in 3 months; if the patient achieves A1c <7%, continue the current regimen and monitor every 6 months. 1
Check vitamin B12 levels now if the patient has been on metformin for ≥4 years, as long-term use impairs absorption and can cause deficiency-related neuropathy. 4
If A1c remains >8% after 3 months on maximally tolerated GLP-1 therapy, consider adding basal insulin (e.g., insulin glargine) while continuing both metformin and the GLP-1 agonist. 1